TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 15685837

Group type: EXPERIMENTAL
Intervention: FEC100 regimen
Number of subjects: 0

Group type: COMPARATOR
Intervention: FEC50 regimen
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cost per year of life saved
Number of subjects: 0
Study: 11581083

Group type: EXPERIMENTAL
Intervention: Dispatcher assistance
Number of subjects: 150

Group type: COMPARATOR
Intervention: No dispatcher assistance
Number of subjects: 150
Study: 9513583

Group type: EXPERIMENTAL
Intervention: Pranlukast (225 mg twice daily for 8 weeks)
Number of subjects: 11
Study: 7844297

Group type: EXPERIMENTAL
Intervention: 10 percent carbamide peroxide bleaching gel (short application time)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: 10 percent carbamide peroxide bleaching gel (extended application time)
Number of subjects: 24
Study: 3132124

Group type: EXPERIMENTAL
Intervention: Gabexate
Number of subjects: 20

Group type: COMPARATOR
Intervention: Heparin
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Gabexate (in patients with bleeding tendencies)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Heparin (in patients with bleeding tendencies)
Number of subjects: 20
Study: 31379269

Group type: EXPERIMENTAL
Intervention: Synbiotic supplementation (15 g of prebiotics, 5 g of probiotics containing Lactobacillus acidophilus T16, Bifidobacterium bifidum BIA-6, Bifidobacterium lactis BIA-7, and Bifidobacterium longum BIA-8 (2.7×107 CFU/g each))
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Probiotic supplementation (5 g probiotics with 15 g of maltodextrin as placebo)
Number of subjects: 75

Group type: COMPARATOR
Intervention: Placebo (20 g of maltodextrin)
Number of subjects: 75
Study: 29161113

Group type: EXPERIMENTAL
Intervention: Cogmed
Number of subjects: 68

Group type: COMPARATOR
Intervention: Waitlist control
Number of subjects: 68
Study: 29231426

Group type: EXPERIMENTAL
Intervention: Row acupuncture at the gaps between phalanges (group A)
Number of subjects: 71

Group type: COMPARATOR
Intervention: Physical therapy (group B)
Number of subjects: 71
Study: 25467221

Group type: EXPERIMENTAL
Intervention: Nabilone (NAB) 0.5 mg to 3.0 mg
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo (PBO)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Nabilone (NAB)
Number of subjects: 10
Study: 23246307

Group type: EXPERIMENTAL
Intervention: DTaP-IPV-Hep B-PRP-T vaccine (Hexaxim)
Number of subjects: 1270
Study: 21586234

Group type: EXPERIMENTAL
Intervention: Telbivudine 600 mg daily for 52 weeks
Number of subjects: 180

Group type: COMPARATOR
Intervention: Entecavir 0.5 mg daily for 52 weeks
Number of subjects: 180
Study: 18363087

Group type: EXPERIMENTAL
Intervention: 8 mm tip radiofrequency (RF) ablation
Number of subjects: 62

Group type: COMPARATOR
Intervention: Cryocatheter (cryo) ablation
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Both RF and cryo ablation
Number of subjects: 62
Study: 16549733

Group type: EXPERIMENTAL
Intervention: Prophylactic antibiotics (3 doses of 1200 mg intravenous amoxicillin-clavulanate at induction and 6 and 12 hours postoperatively)
Number of subjects: 164

Group type: COMPARATOR
Intervention: Postoperative antibiotics (7-day course of 375 mg amoxicillin-clavulanate 3 times a day)
Number of subjects: 164
Study: 14581419

Group type: EXPERIMENTAL
Intervention: Long-term adjuvant androgen deprivation (LTAD) with goserelin for 24 months after initial AD with external-beam radiotherapy (RT)
Number of subjects: 1554

Group type: EXPERIMENTAL
Intervention: Long-term adjuvant androgen deprivation (LTAD) with goserelin for 24 months after initial AD with external-beam radiotherapy (RT) in patients with Gleason scores of 8 to 10
Number of subjects: 1554

Group type: COMPARATOR
Intervention: Short-term adjuvant androgen deprivation with radiotherapy (STAD-RT)
Number of subjects: 1554
Study: 10956572

Group type: EXPERIMENTAL
Intervention: rTMS
Number of subjects: 29
Study: 8781792

Group type: EXPERIMENTAL
Intervention: Endoscopic heat probe therapy (median 165 J) at 24 hours
Number of subjects: 40

Group type: COMPARATOR
Intervention: No retreatment
Number of subjects: 40
Study: 1627435

Group type: EXPERIMENTAL
Intervention: Chemotherapy with oral LMF (fluorouracil, 500 mg, methotrexate, 25 mg, and chlorambucil, 10 mg, on day 1; fluorouracil, 500 mg, and chlorambucil, 10 mg, on day 2)
Number of subjects: 574

Group type: COMPARATOR
Intervention: Control group (no further treatment)
Number of subjects: 574

Group type: EXPERIMENTAL
Intervention: Chemotherapy with oral LMF
Number of subjects: 574

Group type: EXPERIMENTAL
Intervention: Analysis of various prognostic factors
Number of subjects: 574
Study: 6547563

Group type: EXPERIMENTAL
Intervention: 1,25-dihydroxycholecalciferol (1,25(OH)2D3)
Number of subjects: 2

Group type: EXPERIMENTAL
Intervention: Oestrogen/gestagen treatment
Number of subjects: 2

Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 2
Study: 3532401

Group type: EXPERIMENTAL
Intervention: Chrysanol (calcium‐aurothiopropanol‐sulfonate) plus nonsteroid antiinflammatory drugs (NAD)
Number of subjects: 21

Group type: COMPARATOR
Intervention: Control group (NAD only)
Number of subjects: 21
Study: 29369123

Group type: EXPERIMENTAL
Intervention: Tablet computer (intervention group)
Number of subjects: 82

Group type: COMPARATOR
Intervention: Standard care (control group)
Number of subjects: 82
Study: 27679965

Group type: EXPERIMENTAL
Intervention: Therapeutic Hypothermia after Pediatric Cardiac Arrest Out‐of‐Hospital trial
Number of subjects: 295
Study: 23780517

Group type: EXPERIMENTAL
Intervention: Individual education on pulse palpation by a trained nurse
Number of subjects: 205
Study: 23372088

Group type: EXPERIMENTAL
Intervention: Facial cues associated with perceived height and masculinity in wartime context
Number of subjects: 0

Group type: COMPARATOR
Intervention: Facial cues associated with perceived height and masculinity in peacetime context
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Increasing cues of apparent height and masculinity in faces
Number of subjects: 0
Study: 20385692

Group type: EXPERIMENTAL
Intervention: 10 min training with verbal feedback
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: 20 min training with verbal feedback
Number of subjects: 43
Study: 27950666

Group type: COMPARATOR
Intervention: Concomitant CT/RT (Arm A)
Number of subjects: 101

Group type: EXPERIMENTAL
Intervention: Neoadjuvant chemotherapy with TPF followed by concomitant CT/RT (Arm B)
Number of subjects: 101
Study: 16629429

Group type: EXPERIMENTAL
Intervention: Multidisciplinary inpatient rehabilitation for an average of 35.5 days
Number of subjects: 90

Group type: COMPARATOR
Intervention: No treatment (control group)
Number of subjects: 90
Study: 14974922

Group type: EXPERIMENTAL
Intervention: GH treatment (33 microg/kg/day)
Number of subjects: 87

Group type: COMPARATOR
Intervention: GH treatment (66 microg/kg/day)
Number of subjects: 87
Study: 10826408

Group type: COMPARATOR
Intervention: Diet 2: L‐arginine enriched by natural foods
Number of subjects: 6

Group type: COMPARATOR
Intervention: Diet 3: identical to Diet 1 plus oral L‐arginine supplement
Number of subjects: 6
Study: 8649712

Group type: EXPERIMENTAL
Intervention: Once-daily gentamicin dosing (5 mg/kg)
Number of subjects: 127

Group type: COMPARATOR
Intervention: 8-hour gentamicin dosing (1.75 mg/kg every 8 hours)
Number of subjects: 127
Study: 1341599

Group type: COMPARATOR
Intervention: Nicotine polacrilex 0 mg (placebo)
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Nicotine polacrilex 2 mg
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Nicotine polacrilex 4 mg
Number of subjects: 35
Study: 6149772

Group type: EXPERIMENTAL
Intervention: Dextroamphetamine 30 mg
Number of subjects: 10
Study: 29952863

Group type: EXPERIMENTAL
Intervention: Repetitive transcranial magnetic stimulation (rTMS) delivered at 120% motor threshold, 10 Hz, 5-second train duration, and 10-second intertrain interval for 30 minutes weekly for 5 weeks (30,000 stimuli)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Sham rTMS
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Repetitive transcranial magnetic stimulation (rTMS)
Number of subjects: 8
Study: 30031385

Group type: EXPERIMENTAL
Intervention: 10th IRSD decile (least disadvantaged)
Number of subjects: 300
Study: 27615005

Group type: EXPERIMENTAL
Intervention: Morning group (MG, 9:00‐11:00 AM)
Number of subjects: 67

Group type: COMPARATOR
Intervention: Evening group (EG, 9:00‐11:00 PM)
Number of subjects: 67
Study: 24350804

Group type: EXPERIMENTAL
Intervention: REQ-Mobile (smartphone application)
Number of subjects: 102

Group type: COMPARATOR
Intervention: onQ (text messaging system)
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: Both services (REQ-Mobile and onQ)
Number of subjects: 102
Study: 22954866

Group type: EXPERIMENTAL
Intervention: HIV prevention or general health intervention using social networking technologies
Number of subjects: 0
Study: 20102867

Group type: EXPERIMENTAL
Intervention: Clopidogrel
Number of subjects: 2340

Group type: COMPARATOR
Intervention: TIMI risk score alone
Number of subjects: 2340

Group type: EXPERIMENTAL
Intervention: TIMI risk score with STRes added
Number of subjects: 2340

Group type: EXPERIMENTAL
Intervention: Inclusion of STRes to TIMI risk score
Number of subjects: 2340

Group type: EXPERIMENTAL
Intervention: STRes in ExTRACT-TIMI 25 trial
Number of subjects: 2340
Study: 18407386

Group type: EXPERIMENTAL
Intervention: Two doses of MenC conjugate vaccine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Three doses of MenC conjugate vaccine
Number of subjects: 0
Study: 15764631

Group type: EXPERIMENTAL
Intervention: Propofol 6%
Number of subjects: 55

Group type: COMPARATOR
Intervention: Midazolam
Number of subjects: 55
Study: 12365325

Group type: EXPERIMENTAL
Intervention: Immunocorrecting treatment with leukinferone
Number of subjects: 0

Group type: COMPARATOR
Intervention: Etiotropic therapy
Number of subjects: 0
Study: 9676889

Group type: EXPERIMENTAL
Intervention: Alcohol (0.85 g/kg)
Number of subjects: 115

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 115
Study: 7978173

Group type: EXPERIMENTAL
Intervention: Ondansetron (8 mg)
Number of subjects: 271

Group type: COMPARATOR
Intervention: Droperidol (1.25 mg)
Number of subjects: 271

Group type: EXPERIMENTAL
Intervention: Both drugs
Number of subjects: 271
Study: 2644749

Group type: EXPERIMENTAL
Intervention: 2 ml of glucose-free 2% lignocaine
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: 3 ml of glucose-free 2% lignocaine
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: 4 ml of glucose-free 2% lignocaine
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: 3-4 ml of glucose-free 2% lignocaine
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Higher doses of glucose-free 2% lignocaine
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Higher cephalad spread of analgesia
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Falls in systolic blood pressure greater than 30%
Number of subjects: 64
Study: 766574

Group type: EXPERIMENTAL
Intervention: practolol, 15 mg
Number of subjects: 20

Group type: COMPARATOR
Intervention: saline (placebo)
Number of subjects: 20
Study: 31695330

Group type: EXPERIMENTAL
Intervention: Generic formulation under fasting conditions
Number of subjects: 49

Group type: COMPARATOR
Intervention: Branded formulation under fasting conditions
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: Generic formulation under fed conditions
Number of subjects: 49

Group type: COMPARATOR
Intervention: Branded formulation under fed conditions
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: Food intake before administration
Number of subjects: 49
Study: 29998506

Group type: EXPERIMENTAL
Intervention: Post-HTx sST2 levels ≥35 ng/mL (Group 2)
Number of subjects: 62

Group type: COMPARATOR
Intervention: Post-HTx sST2 levels <35 ng/mL (Group 1)
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Post-HTx sST2 levels
Number of subjects: 62
Study: 26897268

Group type: EXPERIMENTAL
Intervention: Nucleated red blood cell (NRBC) count in patients with HDP
Number of subjects: 282

Group type: EXPERIMENTAL
Intervention: Systolic/diastolic (S/D) ratios of fetal ductus venosus, umbilical artery and middle cerebral artery
Number of subjects: 282

Group type: EXPERIMENTAL
Intervention: NRBC count and S/D ratios in diagnosing HDP
Number of subjects: 282

Group type: EXPERIMENTAL
Intervention: Correlation of NRBC and S/D ratios with various clinical parameters
Number of subjects: 282

Group type: EXPERIMENTAL
Intervention: NRBC count
Number of subjects: 282
Study: 24176780

Group type: EXPERIMENTAL
Intervention: 60 minutes/day, 6 days/week of moderate-to-vigorous intensity exercise
Number of subjects: 100
Study: 22079927

Group type: COMPARATOR
Intervention: 10-mg hydrocortisone
Number of subjects: 0
Study: 18752726

Group type: EXPERIMENTAL
Intervention: Citalopram (20 mg/d)
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Reboxetine (8 mg/d)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 42
Study: 17513631

Group type: EXPERIMENTAL
Intervention: Propofol (1.5 microg/mL)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Remifentanil (0.05 microg x kg(‐1) x min(‐1))
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Remifentanil (0.025 microg x kg(‐1) x min(‐1))
Number of subjects: 15

Group type: COMPARATOR
Intervention: Control (no propofol or remifentanil)
Number of subjects: 15
Study: 15204248

Group type: EXPERIMENTAL
Intervention: Off-pump CABG (OPCAB)
Number of subjects: 52

Group type: COMPARATOR
Intervention: On-pump CABG (CPB)
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 52
Study: 11579243

Group type: EXPERIMENTAL
Intervention: Substituted protease inhibitor(s) with abacavir, nevirapine, adefovir and hydroxyurea (n = 49)
Number of subjects: 81

Group type: COMPARATOR
Intervention: Continued all therapy (n = 32)
Number of subjects: 81
Study: 9360756

Group type: EXPERIMENTAL
Intervention: Cetirizine (10 mg OD)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Loratadine (10 mg OD)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (untreated patients)
Number of subjects: 0
Study: 8250311

Group type: EXPERIMENTAL
Intervention: 150 micrograms of clonidine (2-2.5 micrograms/kg)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: 300 micrograms of clonidine (4-4.5 micrograms/kg)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study: 3319648

Group type: EXPERIMENTAL
Intervention: Glipizide treatment for 8 weeks
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 30511959

Group type: COMPARATOR
Intervention: Control group (34 patients with cervical trauma)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Degeneration group and herniation group
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Mild, moderate, and severe groups (based on preoperative JOA scores)
Number of subjects: 90
Study: 28784142

Group type: EXPERIMENTAL
Intervention: Accountable Care Condition (4 clinics, 16 CHW)
Number of subjects: 900

Group type: COMPARATOR
Intervention: Standard Care Condition (4 clinics, 21 CHW)
Number of subjects: 900
Study: 25330096

Group type: EXPERIMENTAL
Intervention: Agomelatine (single-dose)
Number of subjects: 124

Group type: COMPARATOR
Intervention: Placebo (single-dose)
Number of subjects: 124
Study: 23522121

Group type: EXPERIMENTAL
Intervention: Exenatide QW
Number of subjects: 641
Study: 20813349

Group type: EXPERIMENTAL
Intervention: Fluoride Gel followed by no rinsing for 30 minutes
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Fluoride Foam followed by no rinsing for 30 minutes
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Fluoride Gel followed by rinsing with water
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Fluoride Foam followed by rinsing with water
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study: 19120502

Group type: EXPERIMENTAL
Intervention: Replacement of unflued gas heaters with more effective, non-polluting heaters
Number of subjects: 350

Group type: COMPARATOR
Intervention: Unflued gas heaters
Number of subjects: 350

Group type: COMPARATOR
Intervention: Gas stove-tops
Number of subjects: 350

Group type: COMPARATOR
Intervention: Heat pumps, flued gas heating, or enclosed wood burners
Number of subjects: 350
Study: 16290290

Group type: EXPERIMENTAL
Intervention: 80 mg atorvastatin for 6 weeks
Number of subjects: 80

Group type: COMPARATOR
Intervention: Placebo for 6 weeks
Number of subjects: 80
Study: 14551554

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 10965647

Group type: EXPERIMENTAL
Intervention: 6-week treatment condition (applied relaxation and problem solving via the Internet and E-mail)
Number of subjects: 102

Group type: COMPARATOR
Intervention: Waiting-list control
Number of subjects: 102
Study: 8991751

Group type: EXPERIMENTAL
Intervention: Promotion program intervention in 28 nursing homes, including presentations by post-graduate medical students to nursing personnel and residents.
Number of subjects: 55

Group type: COMPARATOR
Intervention: Control group (remaining nursing homes not receiving the intervention).
Number of subjects: 55
Study: 8198213

Group type: EXPERIMENTAL
Intervention: Ethanol (0.6 g/kg)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: 4‐hr TIB and ethanol
Number of subjects: 12

Group type: COMPARATOR
Intervention: 4‐hr TIB and placebo
Number of subjects: 12

Group type: COMPARATOR
Intervention: 8‐hr TIB and placebo
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: 8‐hr TIB and ethanol
Number of subjects: 12
Study: 3478440

Group type: EXPERIMENTAL
Intervention: Sodium hyaluronate
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Corticosteroid (betamethasone)
Number of subjects: 24
Study: 31786121

Group type: EXPERIMENTAL
Intervention: Atezolizumab plus nab-paclitaxel
Number of subjects: 902

Group type: COMPARATOR
Intervention: Placebo plus nab-paclitaxel
Number of subjects: 902
Study: 29018885

Group type: EXPERIMENTAL
Intervention: Fasting Plasma Glucose (FPG)
Number of subjects: 1349

Group type: EXPERIMENTAL
Intervention: 2 h post-load glucose (2hPG)
Number of subjects: 1349

Group type: EXPERIMENTAL
Intervention: HbA1c
Number of subjects: 1349

Group type: EXPERIMENTAL
Intervention: Fasting Insulin
Number of subjects: 1349

Group type: EXPERIMENTAL
Intervention: HOMA-IR
Number of subjects: 1349
Study: 28514277

Group type: EXPERIMENTAL
Intervention: Incentive choice arm (commitment contract with $30 payment conditional on visit and adherence)
Number of subjects: 110

Group type: EXPERIMENTAL
Intervention: Provider visit incentive arm ($30 after attending each scheduled provider visit)
Number of subjects: 110

Group type: COMPARATOR
Intervention: Passive control arm (routine care with no incentives)
Number of subjects: 110
Study: 25168918

Group type: EXPERIMENTAL
Intervention: Booster dose of influenza vaccination administered 5 weeks after standard vaccination
Number of subjects: 514

Group type: COMPARATOR
Intervention: Standard single dose of influenza vaccination
Number of subjects: 514
Study: 22402056

Group type: EXPERIMENTAL
Intervention: Rivaroxaban 20 mg daily
Number of subjects: 14264

Group type: COMPARATOR
Intervention: Warfarin (adjusted dose, INR 2.0-3.0)
Number of subjects: 14264
Study: 20639824

Group type: EXPERIMENTAL
Intervention: Diclofenac sodium 0.1% eye drop - 1 drop 4 times daily for 30 days after cataract surgery
Number of subjects: 80

Group type: COMPARATOR
Intervention: Prednisolone acetate 1% eye drop - 1 drop 2 hourly for 1 week, then 1 drop 4 hourly for 2 weeks, then 1 drop 6 hourly for 30 days after cataract surgery
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Diclofenac sodium 0.1% eye drop
Number of subjects: 80

Group type: COMPARATOR
Intervention: Prednisolone acetate 1% eye drop
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Visual acuity with pin hole in group-A
Number of subjects: 80

Group type: COMPARATOR
Intervention: Visual acuity with pin hole in group-B
Number of subjects: 80
Study: 17666349

Group type: EXPERIMENTAL
Intervention: Embryos with two pronuclei in close vicinity, central position of the pronuclei in the cytoplasm, and comparable size of the two pronuclei.
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Embryos developed from zygotes with linear arrangement of 3 to 7 NPB in moderate sizes.
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Zygotes with excessive cytoplasmic granularity.
Number of subjects: 62

Group type: COMPARATOR
Intervention: Other morphologic characteristics (polar bodies, color of the cytoplasm, cytoplasm halo, or vacuoles in the cytoplasm).
Number of subjects: 62
Study: 15826265

Group type: EXPERIMENTAL
Intervention: Dexamethasone sodium phosphate
Number of subjects: 40

Group type: COMPARATOR
Intervention: Dexamethasone acetate
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Dexamethasone sodium phosphate and dexamethasone acetate
Number of subjects: 40
Study: 11929350

Group type: EXPERIMENTAL
Intervention: Urokinase plus abciximab
Number of subjects: 70

Group type: COMPARATOR
Intervention: Urokinase alone
Number of subjects: 70
Study: 9506325

Group type: EXPERIMENTAL
Intervention: Calcium channel blockers
Number of subjects: 2120

Group type: EXPERIMENTAL
Intervention: Calcium channel blockers (in SAVE placebo group)
Number of subjects: 2120

Group type: EXPERIMENTAL
Intervention: Calcium channel blockers (in SAVE captopril group)
Number of subjects: 2120
Study: 7918923

Group type: EXPERIMENTAL
Intervention: Pentasa 2 g/day
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Pentasa 4 g/day
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Pentasa 6 g/day
Number of subjects: 13

Group type: COMPARATOR
Intervention: Olsalazine 2 g/day
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Pentasa 4 g/day and 6 g/day
Number of subjects: 13
Study: 3137180

Group type: EXPERIMENTAL
Intervention: L-carnitine
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 28875327

Group type: EXPERIMENTAL
Intervention: 200-μg selenium per day for 8 weeks
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study: 28390695

Group type: EXPERIMENTAL
Intervention: Oral ramipril 10 mg/day (n=8407)
Number of subjects: 30937

Group type: EXPERIMENTAL
Intervention: Oral telmisartan 80 mg/day (n=8386)
Number of subjects: 30937

Group type: EXPERIMENTAL
Intervention: Combination of ramipril and telmisartan (n=8334)
Number of subjects: 30937

Group type: EXPERIMENTAL
Intervention: Oral telmisartan 80 mg/day (n=2903)
Number of subjects: 30937

Group type: COMPARATOR
Intervention: Placebo (n=2907)
Number of subjects: 30937
Study: 26301484

Group type: EXPERIMENTAL
Intervention: Health Locus of Control questionnaire (HLOC)
Number of subjects: 60000

Group type: EXPERIMENTAL
Intervention: HLOC plus AR questionnaire
Number of subjects: 60000

Group type: COMPARATOR
Intervention: No questionnaire (control)
Number of subjects: 60000

Group type: EXPERIMENTAL
Intervention: AR intervention
Number of subjects: 60000

Group type: EXPERIMENTAL
Intervention: Secondary outcomes
Number of subjects: 60000
Study: 23389687

Group type: EXPERIMENTAL
Intervention: Perceived stress
Number of subjects: 3759

Group type: EXPERIMENTAL
Intervention: Life events
Number of subjects: 3759